Background: Early identification of patients at high risk for chemoresistance among those treated with methotrexate (MTX) for low-risk gestational trophoblastic neoplasia (GTN) is needed. We modeled human chorionic gonadotropin (hCG) decline during MTX therapy using a kinetic population approach to calculate individual hCG clearance (CL hCG ) and assessed the predictive value of CL hCG for MTX resistance.
introduction
In 2002, the International Federation of Gynecology and Obstetrics (FIGO) committee classified gestational trophoblastic neoplasias (GTN) as high-risk and low-risk tumors according to the risk of relapse. Classification into one of these two groups is determined by a combination of eight prognostic factors graded from 0 to 4 [1, 2] . In France, low-risk tumors, characterized by a FIGO score £6, are commonly treated with monotherapy, usually the 8-day methotrexate (MTX) regimen modified by Bagshawe et al. and Chalouhi et al. [3, 4] . In cases of MTX resistance or intolerance, patients are switched to actinomycin D (ACT-D) or to etoposide, methotrexate, actinomycin, cyclophosphamide, and vincristine regimen (EMA-CO) regimens, including ACT-D, etoposide, methotrexate, and folinic acid [5] . Although tumor chemoresistance is often defined as an increase or stagnation of human chorionic gonadotropin (hCG) levels over a 2-to 3-week period, there are no clear guidelines concerning the optimal method for analyzing hCG kinetics [5] . Identification of predictive factors that could provide early information about the risk of MTX resistance would be useful [5] .
Recently, authors have proposed hCG titer thresholds as potential predictive factors of chemoresistance. Using hCG decline corridors and receiver operating characteristic (ROC) analyses, hCG cut-offs measured during the seventh week of MTX therapy were proposed: 56 lg/l equivalent to 520.24 mIU/ ml in Van Trommel et al. [6] , 737 mIU/ml in Kerkmeijer et al. [7] , and 500 mIU/ml in Savage et al. [8] studies. These studies might have been limited by the methodology used to characterize hCG decreases, especially by their dependence on a single time point prone to high inter/intraindividual variability. It may explain the heterogeneity in the reported cut-offs.
Herein, we propose a population kinetic approach, relying on modeling and pharmacokinetic principles [9] , to assess individual hCG decrease profiles dynamically. Application of this method has been described for kinetic assessment of other tumor markers [10] [11] [12] . Briefly, combining all patient time points allows to model a population decline profile, to quantify inter-and intraindividual variability, and to determine the individual decline curve equations. The apparent tumor marker clearance (CL), a kinetic parameter, related to marker residual production and elimination, and independent of selected time points, can then be determined.
We postulate that hCG clearance (CL hCG ) would predict accurately the MTX resistance risk in patients with low-risk GTN. The objective of the present study was to assess the feasibility of characterizing MTX resistance using hCG kinetics.
patients and methods

patients
All patient data were derived from the French national registry of the Centre de Référence des Maladies Trophoblastiques based in Lyon [2] . All patients had been treated in French centers for chemonaive low-risk GTN according to 2000 FIGO classification [13] between January 2000 and February 2008. Exclusion criteria included treatment with two or less courses of MTX, patients whose treatment was changed without resistance criteria fixed by the Centre de Référence des Maladies Trophoblastiques or whose treatment differed from the conventional MTX regimen, patients with inadequate hCG follow-up, and historical diagnosis of a placental site trophoblastic tumor.
All patients were treated with the 8-day MTX regimen defined by Bagshawe et al. [3] : intramuscular MTX (1 mg/kg) on days 1, 3, 5, and 7 along with oral folinic acid (10 mg) on days 2, 4, 6, and 8, every 2 weeks. hCG levels were determined once each week. Treatment was stopped if hCG values normalized (£5 mIU/ml) or switched to a second treatment (EMA-CO, ACT-D, or a platinum-based regimen) in the case of tumor MTX resistance or biochemical relapse. If the treatment was altered, further hCG titers were not included in the analysis. Choriocarcinoma diagnoses were confirmed by a pathologist, whereas non-choriocarcinoma diagnoses were defined biologically and not histologically according to 2000 FIGO hCG criteria [1] .
analysis of hCG kinetics A population pharmacokinetic model was developed using a dataset consisting of plasma concentrations of total hCG following MTX administration. The analysis was carried out using data collected between day 0 (day of chemotherapy start) and day 40. Indeed, predicting the resistance risk after three courses of chemotherapy would provide enough time to quickly adapt treatment in patients at high risk of resistance.
The analysis was carried out using a nonlinear mixed-effects modeling strategy, implemented in NONMEM version 6, to estimate the population parameters (mean and intersubject variability) as well as the residual variability. Moreover, it was used to identify potential covariates that could explain intersubject variability of parameters [14] . Linear pharmacokinetic models were evaluated, including one-and two-exponential models for disposition and elimination of hCG. Because the rate of endogenous hCG production was unknown, no attempt was made to characterize it before time 0. Monoexponential models were implemented with the following equation:
whereas biexponential models were implemented with
where hCG ij (t) is the jth measurement determined in patient i at time t, and e1 ij and e2 ij are the proportional and additive residual variability of patient i at the jth measurement, which has a mean of zero and variance of r 2 . Parameters hCG0 i , K i , hCG1 i , hCG2 i , a i , and b i were assumed to vary randomly between patients according to a normal log distribution. Once individual parameters hCG0 i and K i or hCG1 i , hCG2 i , a i , and b i are estimated, it is possible to determine the individual apparent clearance (CL hCGi ). In the monoexponential model, this is equal to the product of K i and the volume of distribution (Vd), where Vd is estimated to be 3.4 l, as described previously [15] . Data analysis was carried out using the first-order conditional estimation method with an interaction computational method algorithm (FOCE INTERACTION). Comparison of two nested models was based on differences between the minimum value of the objective function. The following individual covariates were tested to estimate their impact on hCG kinetic parameters for reducing unexplained interindividual variability: items included in the FIGO score as well as tumor pathology (choriocarcinoma versus nonchoriocarcinoma), number of children, hysterectomy (yes versus no), interval between first and second MTX cycle, and hCG surge after MTX start (yes versus no). The modeling methodology has been described in detail elsewhere [11] .
internal validation of the model: visual predictive check
The predictive performance of the final model was evaluated by visual predictive check (VPC) [16, 17] . We simulated 100 decline profiles for hCG using the final parameters estimated from the best model. The predictive ability of the population pharmacokinetic model was assessed using graphical comparison of the 90% confidence intervals (CIs) of predictions built from simulated data with an overlay of the observed data.
assessment of predictive value of CL hCG
A normal hCG value was considered £5 mIU/ml. MTX resistance is defined by the Centre de Référence des Maladies Trophoblastiques as an increase or a plateau in two consecutive hCG values over a 2-week interval. This definition was chosen to minimize the effects of weekly hCG concentration fluctuations and to establish a similar time interval between two MTX cycles.
One of the aims of the study was to define a CL hCG threshold that could discriminate patients at high risk of MTX resistance from those at lower risk. We used ROC curves to test the diagnostic accuracies of different cutoffs. To optimize statistical power, the thresholds tested were derived from the median and quartiles of CL hCG . Once the best cut-off was identified, we assessed the diagnostic accuracy of the CL hCG ['less than or equal to' (£) threshold versus 'more than' (>) threshold] against other kinetic original article Annals of Oncology parameters reported in literature (seventh-week hCG value £520.24 versus >520.24 mIU/ml [6] , or £737.0 versus >737.0 mIU/ml [7] ) for predicting MTX resistance risk. Because patient distributions were similar when seventh-week hCG cut-off was fixed at 500 or 520 mIU/ml, we did not study the predictive value of threshold reported by Savage et al. (9) .
Moreover, we assessed the predictive value of CL hCG on MTX resistancefree survival (MRFS) using univariate/multivariate survival analyses. MRFS was calculated as the time elapsed between the first MTX course on day 0 and the first event, such as MTX biochemical resistance day or death due to any cause.
The following potential predictive factors were investigated using survival log-rank tests:
Parameters included in the FIGO score except for the previous chemotherapy item because all patients were chemonaive. Other potential predictive covariates: hysterectomy (yes/no), tumor pathology (choriocarcinoma or non-choriocarcinoma), number of MTX courses, number of uterine evacuations, number of children, uterus invasion depth, transient hCG surge after start of MTX (yes/no), interval between first and second MTX courses (£14 versus >14 days), pretreatment hCG scored according to the Chan et al. threshold reported as a predictive factor of failure after one single MTX dose (£5000 versus >5000 mIU/ml) [18] , and hCG level in the seventh week, scored according to the Van Trommel et al. threshold (£520.24 versus >520.24 mIU/ml, equivalent to £56 versus >56 lg/l) [6] and according to Kerkmeijer et al. cut-off (£737.0 versus >737.0 mIU/ml) [7] . Seventhweek hCG values were available for 125 patients. We also assessed the predictive value of CL hCG threshold defined with the ROC curve analysis (£ versus > lower quartile). Because the log-rank test requires categorical data, continuous covariates were split into two groups according to the median except for CL hCG , which was split according to the lower quartiles for the ROC curve analysis.
To determine independent predictive factors, variables found to be statistically significant in univariate analysis (P < 0.05) were included in multivariate analysis using Cox models with backward elimination. Median follow-up was calculated using a reverse Kaplan-Meier estimate [19] . All tests were carried out with S-PLUSä and SPSSä using a two-sided 0.05 alpha risk. The ROC curves were generated using TANAGRAä software.
results patients and follow-up
Data for 154 patients with low-risk GTN were analyzed; 5574 hCG concentration determinations were recorded between October 1999 and March 2008. Modeling analysis was carried out using 845 hCG concentrations determined between day 0 (day of chemotherapy start) and day 40, with a mean of 5.5 observations per patient. Because the data included concentrations below the limit of quantification (BLOQ), the first concentration in a series of BLOQ observations was replaced by LOQ/2 and later observations were censored [20, 21] . Patient characteristics are summarized in Table 1 .
modeling
The best model describing the hCG decrease between day 0 and day 40 was a one-compartment model. All covariates likely to influence the hCG decline profile were evaluated. Only the pretreatment hCG value, scored according to FIGO criteria (shCG0), significantly decreased the unexplained interindividual variability of the modeled hCG0. However, shCG0 could not be inserted into the model as a covariate because it was equivalent to hCG0 grouped by classes. Thus, the final population model was hCGðtÞ = 3900 · e 20:149 · t ;
where hCG(t) was the population-predicted hCG value (mIU/ ml) at time t (days) for data collected between day 0 and day 40. Figure 1 shows the plots leading to the final model selection.
The results for modeled parameters, interindividual variability, 95% CIs, and residual variability are shown in Table  2 . Figure 2 shows the VPC: 96.7% of observed hCG levels fell within the 90% prediction interval, supporting the accuracy of the model.
predictive value of CL hCG
After a median follow-up of 12.7 months (95% CI 11.5-13.4), 133 patients (86%) were not MTX resistant and 21 (14%) had become resistant to MTX. All resistances developed within the first year of initiating treatment (median time to resistance = 83 days; range 48-195 days). These patients all received second-line treatment: EMA-CO, n = 13 (62%); ACT-D, n = 6 (29%); bleomycin, etoposide, cisplatin regimen, n = 1 (5%), or had a hysterectomy, n = 1 (5%). One patient died 91 days after start of chemotherapy.
ROC curve analysis
Several different thresholds, using CL hCG median and quartiles, were evaluated for diagnostic accuracy of MTX resistance by ROC curve analysis. The best area under the ROC curve (AUC) was observed when the lower CL hCG quartile was used (£0.37 versus >0.37 l/day): AUC = 74.5, sensitivity = 66.7%, specificity = 81.2%, positive predictive value (PPV) = 35.9%, and negative predictive value (NPV) = 93.9%.
Because none of the three other tests reported in literature offered a better diagnostic accuracy for detecting resistance risk, we decided to use the cut-off described previously in univariate and multivariate analyses. The seventh-week hCG cut-off of Van Trommel et al. (£520.24 versus >520.24 mIU/ml) had an AUC of 74.5 (sensitivity 44.4%, specificity 91.7%, NPV 89.9%, PPV 50.0%), whereas the seventh-week hCG cut-off of Kerkmeijer et al. (£737.0 versus >737.0 mIU/ml) had an AUC of 72.5 (sensitivity 38.9%, specificity 92.8%, NPV 89.1%, PPV 50.0%; supplemental Figure S1 , available at Annals of Oncology online). Table 3 shows the predictive factors significant in univariate survival analysis using the log-rank test. Six factors predictive of hCG resistance risk were identified: unfavorable CL hCG less than or equal to lower quartile (0.37 l/day), choriocarcinoma tumor pathology, term or abortion pregnancy history, hCG surge after start of chemotherapy, seventh-week hCG >520.2 mIU/ml, and seventh-week hCG >737.0 mIU/ml. These covariates were included in a multivariate survival Cox model. As shown in Table 3 , four factors were initially significant; backward elimination identified two of these as independent significant predictive factors: (i) choriocarcinoma versus nonchoriocarcinoma pathology [hazard ratio (HR) = 6.01; 95% CI Annals of Oncology original article Figure 3 shows the Kaplan-Meier curves of MRFS according to tumor pathology and CL hCG lower quartile threshold.
survival analyses
conclusions
Although there is consensus regarding the use of monotherapy (MTX or ACT-D) for treating low-risk GTN, many aspects of treatment for this patient subgroup remain unclear [5] . Early identifying patients at high risk for MTX resistance would enable rational individualization of treatment protocols [22] . Recently, several studies have identified potential predictive factors of chemoresistance in poor-risk GTN [6-8, 23, 24] .
However, the cut-offs reported in these trials might be limited by their intimate dependences on static and single hCG measurements, prone to high unconsidered inter/ intraindividual variability. It could explain the heterogeneity in the reported thresholds. Moreover, none of the latter studies incorporated survival analysis or regression models to test the predictive values of cut-offs with respect to other prognostic covariates, which is the standard method for validating such factors.
In the present study, we identified two independent predictive factors. Because 50% of patients with a choriocarcinoma were resistant to MTX, this pathology appeared to be a strong negative predictive factor. We also Annals of Oncology original article [18, 25, 26] . Early MTX discontinuation might rather be considered in patients with MTX-sensitive tumors and thereby more likely to be cured. Stop of treatment might thus be considered after three chemotherapy cycles in patients with high CL hCG , whereas MTX continuation until hCG normalization or change of chemotherapy regimen could be discussed in patients with low CL hCG . Of course, this assumption was not directly raised in the present study and will have to be assessed in other studies. These results reported herein should be interpreted with caution because this study included small numbers of patients and MTX resistance events, although it is the second largest study on this particular subgroup to date. The results we present relate to our cohort but might not be applicable to another group of patients. The data used in the analysis were not derived from a specifically designed study with highly selected patients and favorable conditions likely to aid in predictive factor identification but conformed to 'real-life' patient data (treatment in various French hospitals, hCG concentrations determined in different laboratories using various immunoassay kits). Despite these limitations that were likely to increase inter-and intraindividual variability and to scatter modeled CL hCG values, our results were highly statistically significant. CL hCG values were calculated on the assumption that body hCG distribution was equal to the blood volume distribution, as indicated by Norman et al. [15] . Three elements could explain the 'traditional' prognostic factors, such as FIGO items, FIGO score [25, 27] , or metastasis status [18] , that were not found significant in the multivariate analysis. The limited number of patients might have contributed to the reduced statistical power of analysis. Moreover, these factors were reported in studies carried out before the definition of low-risk GTN by FIGO in 2000, thereby including patients with various disease stages. Finally, these factors have not been confronted with hCG kinetic parameters in univariate/ multivariate analyses within articles published so far.
This study confirms that it is possible to model individual hCG decline curves using a kinetic population approach in low-risk GTN patients. Using univariate and multivariate survival analyses, our results showed that patients with choriocarcinoma and treated with MTX have a high risk of MTX resistance. Using this modeled CL hCG approach, it might be possible to identify a subgroup of patients likely to develop MTX resistance who might benefit from early treatment alterations. Other retrospective studies involving higher numbers of patients, potentially followed by prospective trials, are warranted to confirm the relevance of CL hCG in managing patients with low-risk GTN. 
